Editorial Staff

Clinical Editor
Morton Kern, MD
Executive Editor
Laurie Gustafson
Managing Editor
Rebecca Kapur
Production Manager
Elizabeth Vasil

Editorial Correspondence

Rebecca Kapur, Managing Editor, Cath Lab Digest
HMP Communications, 70 E. Swedesford Rd
Suite 100, Malvern PA 19355
Telephone: (440) 717-0418

Fax: (866) 896-8762
Email: rkapur@hmpglobal.com

August 2014

|
Volume 22 Issue 8
This fascinating case by Dr. Jon George brings to mind some of the biggest controversies in interventional cardiology.
This month: hot topics re: staffing and med administration
The Swedish Heart and Vascular Institute includes three state-of-the-art cardiac catheterization labs, one of which is specialized for peripheral endovascular intervention and 3-dimensional (3D) vessel reconstruction imaging. We also utilize a hybrid…
The following case is the second in a series of transradial-focused reports, directed by section editor Dr. Samir Pancholy. This case series is supported by an educational grant from Medtronic.
PICSO is designed to increase myocardial perfusion in conjunction with primary percutaneous coronary intervention (PCI) and thereby reduce infarct size and improve cardiac function. To date, nearly 160 patients have been treated, and the most recent…
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally invasive procedure.
Older registered nurses are working longer than in the past, one reason that the nation’s supply of RNs has grown substantially in recent years, according to a new study.
Boston Scientific Corporation has received FDA approval for the Rebel Platinum Chromium Coronary Stent System, the company’s latest generation bare-metal stent for the treatment of coronary artery disease (CAD). The company announced CE Mark for the…
Boston Scientific Corporation has initiated full commercial launch of the new Polaris Imaging System.
In mice with diet-induced diabetes — the equivalent of type 2 diabetes in humans — a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days.